Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Presendin's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Presendin.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Presendin | Invex Therapeutics | Small Molecule Other | Phase 3 | 0 | ||||
| Tirzepatide in Idiopathic Intracranial Hypertension Trial | Duke University | — | Phase 4 | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment | Capital Medical University | — | Phase 3 | — | — | — | — | — |
| Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) | Beijing Tiantan Hospital | — | Phase 3 | — | — | — | — | — |